课题基金 / 基金详情

Mechanism and Function of Endoplasmic Reticulum Protein Quality Control Machinery In The Maintenance of Hematopoietic Stem Cells

Mechanism and Function of Endoplasmic Reticulum Protein Quality Control Machinery In The Maintenance of Hematopoietic Stem Cells
内质网蛋白质控机制在造血干细胞维持中的作用机制及作用
批准号:
10594513
负责人:
Xi Chen
金额:
$50.04万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-04-01 至 2025-03-31

项目摘要

项目成果

Xi Chen的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 造血干细胞(HSCs)在应激时维持组织稳态和补充血液系统。 HSC已经进化出独特的机制来维持整个生命过程中基因组和蛋白质组的完整性。而 基因组完整性保护机制已被广泛研究,但对蛋白质组如何保护基因组完整性知之甚少。 完整性在HSC中维持,以及休眠的HSC如何被保护免受蛋白质损伤, 发育和生理压力。这项建议将弥补这一知识差距。我们最近发现 Sel 1 L ER相关降解(ERAD)途径在维持 HSC。ERAD是主要的蛋白质质量控制机制,负责靶向错误折叠的蛋白质, ER用于胞质蛋白酶体降解。Sel 1 L-Hrd 1复合物是最保守的分支, ERAD。使用条件性基因敲除小鼠模型,我们发现造血细胞中Sel 1 L缺失 显著降低稳态HSC频率,并导致HSC重建能力完全丧失, 应激条件包括骨髓移植和5-氟尿嘧啶(5-FU)介导的骨髓消融。 有趣的是,Sel 1 L缺失不会诱导细胞凋亡或损害HSC植入。相反,我们观察到, Sel 1 L基因敲除小鼠中HSC循环增加和静止HSC数量减少。这些数据 证明Sel 1 LERAD在HSC维持中的关键功能,并提出ER蛋白的新作用 质量控制机制在调节干细胞静止和自我更新。ERAD监测和调节 跨膜蛋白的成熟。我们发现CXCR 4的表面表达显著降低, MPL是Sel 1 L敲除HSC中HSC静止和生态位相互作用的两个主要调节因子。跟踪HSC 在体内单细胞水平的小生境细胞显示Sel 1 L缺陷的HSC在骨中的异常定位 骨髓龛我们推测Sel 1 LERAD通过调节HSC的活动来调控HSC的静止和自我更新 跨膜受体成熟和HSC-生态位相互作用。我们将建立生理意义 Sel 1 LERAD在HSC维持中的作用(目的1),确定ERAD的意义和机制。 目的2:探讨HSC中未折叠蛋白反应(UPR)串扰的机制及意义。 HSC-生态位相互作用中的Sel 1 LERAD(目的3)。这项研究将提供重要的洞察后- 通过ER蛋白质质量控制对HSC静止、自我更新和生态位相互作用的翻译调节 机制,并进一步确定HSC命运的新决定因素。
英文摘要
ABSTRACT Hematopoietic stem cells (HSCs) maintain tissue homeostasis and replenish blood system upon stresses. HSCs have evolved unique mechanisms to maintain genome and proteome integrity throughout life. While the genome integrity safeguard mechanisms have been extensively studied, little is known about how proteome integrity is maintained in HSCs and how dormant HSCs are protected from protein damage during development and physiological stresses. This proposal will address this knowledge gap. We recently found that the Sel1L ER-associated degradation (ERAD) pathway plays an essential role in the maintenance of HSCs. ERAD is the principal protein quality control mechanism responsible for targeting misfolded proteins in the ER for cytosolic proteasomal degradation. The Sel1L-Hrd1 complex is the most conserved branch of ERAD. Using a conditional knockout mouse model, we found that Sel1L deletion in hematopoietic cells significantly reduced steady-state HSC frequency and led to complete loss of HSC reconstitution capacity in stress conditions including bone marrow transplantation and 5-fluorouracil (5-FU) mediated myeloablation. Interestingly, Sel1L deletion did not induce apoptosis or impair HSC engraftment. In contrast, we observed increased HSC cycling and reduced numbers of quiescent HSCs in Sel1L knockout mice. These data demonstrate the critical function of Sel1L ERAD in HSC maintenance and suggest a novel role for ER protein quality control machinery in regulating stem cell quiescence and self-renewal. ERAD monitors and regulates the maturation of transmembrane proteins. We found markedly decreased surface expression of CXCR4 and MPL, two master regulators of HSC quiescence and niche interaction, in Sel1L-knockout HSCs. Tracking HSC and niche cells at the single cell level in vivo showed aberrant localization of Sel1L-deficient HSCs in the bone marrow niche. We hypothesize that Sel1L ERAD governs HSC quiescence and self-renewal by regulating HSC transmembrane receptor maturation and HSC-niche interaction. We will establish the physiological significance of Sel1L ERAD in the maintenance of HSCs (Aim 1), determine the significance and mechanism of the ERAD- Unfolded Protein Response (UPR) crosstalk in HSCs (Aim 2), and elucidate the mechanism and significance of Sel1L ERAD in HSC-niche interactions (Aim 3). This study will provide significant insight into the post- translational regulation of HSC quiescence, self-renewal, and niche interaction by ER protein quality control mechanisms, and further identify novel determinants of HSC fates.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
High-throughput closed-loop direct aberration sensing and correction for multiphoton imaging in live animals
  • 批准号:
    10572572
  • 项目类别:
  • 资助金额:
    $10.41万
  • 财政年份:
    2023
  • 负责人:
    Xi Chen
  • 依托单位:
Crosstalk between the ER Stress Response and Mitochondrial Fatty Acid Oxidation in MYC-driven Breast Cancer
  • 批准号:
    10581179
  • 项目类别:
  • 资助金额:
    $35.87万
  • 财政年份:
    2023
  • 负责人:
    Xi Chen
  • 依托单位:
Proteostasis Reprogramming in Mutant KRAS-Driven Cancers
  • 批准号:
    10587281
  • 项目类别:
  • 资助金额:
    $51.54万
  • 财政年份:
    2022
  • 负责人:
    Xi Chen
  • 依托单位:
A Life Course Approach to Understanding Racial and Ethnic Disparities in Alzheimer's Disease and Related Dementias and Health Care
  • 批准号:
    10650381
  • 项目类别:
  • 资助金额:
    $72.78万
  • 财政年份:
    2022
  • 负责人:
    Xi Chen
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: